Literature DB >> 25180718

Counterpoint: Is an increase in FEV₁ and/or FVC ≥ 12% of control and ≥ 200 mL the best way to assess positive bronchodilator response? No.

James E Hansen1, Janos Porszasz2.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 25180718     DOI: 10.1378/chest.14-0437

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  4 in total

1.  A New Bronchodilator Response Grading Strategy Identifies Distinct Patient Populations.

Authors:  James E Hansen; Asli G Dilektasli; Janos Porszasz; William W Stringer; Youngju Pak; Harry B Rossiter; Richard Casaburi
Journal:  Ann Am Thorac Soc       Date:  2019-12

2.  Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease.

Authors:  Pierre-Régis Burgel; Vincent Le Gros; Laurent Decuypère; Isabelle Bourdeix; Thierry Perez; Gaëtan Deslée
Journal:  BMC Pulm Med       Date:  2017-01-31       Impact factor: 3.317

3.  The paradoxical response to short-acting bronchodilator administration in patients with chronic obstructive pulmonary disease.

Authors:  Hong-Joon Shin; Tae-Ok Kim; Yu-Il Kim; Sang-Hoon Kim; Hyun Kuk Kim; Yong-Hyun Kim; Min Kwang Byun; Ki-Suck Jung; Kwang-Ha Yoo; Jae Seung Lee; Sung-Chul Lim
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

4.  Area Under the Expiratory Flow-Volume Curve (AEX): Assessing Bronchodilator Responsiveness.

Authors:  Octavian C Ioachimescu; James K Stoller
Journal:  Lung       Date:  2020-03-24       Impact factor: 2.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.